Trasylol

Manufactured by Bayer, Trasylol is an injection used in to prevent excessive blood loss during heart bypass surgery. However, Trasylol has put patients at an increased risk of death. Studies have shown that more than 6% of patients injected with Trasylol died within 30 days of surgery.

In Nov. 2007, the drug was removed from the market after a Canadian study stopped because patients injected with Trasylol were dying more often than other patients in the study. Prior to the Canadian study, Dr. Dennis Mangano provided the FDA with research that Trasylol increased the chance of kidney failure. His study also reported that the drug increased by chance of death by 50%. Bayer representatives met with Mangano, defended Trasylol and allowed it to stay on the market. However, Bayer failed to alert the FDA of their own studies that confirmed the doctor’s findings. Research conducted by Bayer found that risk of death in patients injected with Trasylol was 64% higher than other patients.

After Mangano’s meeting with Bayer, the FDA issued Trasylol a black box warning to alert patients of the increased risk of death and kidney failure. The label also advised that Trasylol should only be used for those at a high risk of blood loss during surgery.

If you or a loved one has died because of a Trasylol injection, you may be able to seek compensation. Contact a skilled attorney today.